H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

James Hamilton; Chief of Discovery and Translational Medicine; Arrowhead Pharmaceuticals Inc. Kenneth Myszkowski; Chief Financial Officer; Arrowhead Pharmaceuticals Inc. Unidentif ...

Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

LIXTE Biotechnology (LIXT) has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common ...

Bradley Chhay; Chief Financial Officer; RCI Hospitality Holdings Inc. Scott Buck; Analyst; H.C. Wainwright & Co.